The FGFR family as drivers and biomarkers of regorafenib response in gastric cancer.

FGFR 家族作为胃癌瑞格非尼反应的驱动因素和生物标志物。

• 批准号: nhmrc : 1126094
• 负责人: A/Pr Niall Tebbutt
• 金额: $ 45.74万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/fgfr-family-drivers-gastric-cancer/947731
• 关键词: FGFR; family; drivers; biomarkers; regorafenib

The drug regorafenib has recently emerged as a potential new treatment for patients with gastric (stomach) cancer. We have discovered that gastric cancer cell lines which express high levels of members of the FGFR family are highly sensitive to this drug. This project will define the potential of targeting the FGFR family in gastric cancer,the value of FGFR1-4 as markers of regorafenib response, and develop strategies for enhancing regorafenib activity in this difficult to treat disease.

药物瑞戈非尼最近成为胃癌患者的潜在新治疗方法。我们发现，表达高水平FGFR家族成员的胃癌细胞系对该药物高度敏感。该项目将确定胃癌中靶向FGFR家族的潜力，FGFR 1 -4作为瑞格非尼反应标志物的价值，并制定增强瑞格非尼在这种难以治疗的疾病中的活性的策略。